Stock Screener App

無料 -

インストール

Drug Manufacturers - General

51.69

1.87% 0.95

after-market

アフターアワーズ： 51.69

Sanofi Adr (SNY)

概要ニュース株価時系列オプションチェーンなぜSNYが下落しているのか？ディスカッション予測株の配当実績

Sanofi Adr (SNY) 最新ニュース

Bronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight - GlobeNewswire Inc.

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.

Gsk Plc ADR (GSK-N) QuotePress Release - The Globe and Mail

Communiqué de presse - GlobeNewswire Inc.

Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 90-Plus RS Rating - Investor's Business Daily

10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar

Teva Catapults 26%, Hitting A Six-Year High, After Scoring A Win With Sanofi-Tied Drug - Investor's Business Daily

What Did We Find About Insider Trading At Sanofi ADR (NASDAQ: SNY)? - Stocks Register

Weekly Upgrades and Downgrades - InvestorPlace

Upcoming Nasdaq-100 changes could boost the stocks of these 11 companies - MSN

Teva Pharmaceutical ADR Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily

Top-3 International Stocks Beating Their U.S. Peers for Dividend Earnings - TheStreet

Teva Pharmaceutical ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily

Novo Nordisk and AstraZeneca top 2025 drug picks for US investment bankread why - Proactive Investors USA

Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest in? - Insider Monkey

12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.

How Robert F. Kennedy Jr. Will Bring Major Uncertainties to U.S. Healthcare - Barron's

Sanofi Cancels Consumer Healthcare Business Spin-Off - Forbes

GILD

$92.96

1.22%

AMGN

$274.81

0.99%

PFE

$26.64

1.29%

NVS

$99.73

2.26%

MRK

$96.24

1.72%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く